Inogen

Q2 FY2026 EarningsQ2 FY26 results were mixed with a slight revenue miss and in-line margins. Total revenue reached $95.1M, slightly below the $95.2M consensus. International sales growth of 14.8% was offset by an 11.8% decline in U.S. rental revenue due to lower patient volume. Gross margin of 45.5% slightly exceeded the 44.9% mean estimate, driven by manufacturing efficiencies and lower component premiums. GAAP EPS of -$0.14 was nominally better than the -$0.15 consensus, aided by a modest beat in operating loss ($5.1M actual vs. $5.1M expected), despite a sharp decline in interest income.